



Fidson Healthcare Plc RC 267435

Corporate Head Office:
268, Ikorodu Road, Obanikoro,
P.O.Box 7210, Shomolu, Lagos.
Tel: +234 807 700 8888,
+234 01-3429102,
e-mail: info@fidson.com
www.fidson.com

FIDSON HEALTHCARE PLC

Thursday, 16th of November 2023

Lagos, Nigeria

Press Release:

FIDSON HEALTHCARE ANNOUNCES STRATEGIC COOPERATION WITH A LEADING CHINESE PHARMACEUTICAL COMPANY

In a bid to further add value to the healthcare landscape in Nigeria and Africa, Fidson Healthcare Plc (Fidson), a foremost Nigerian pharmaceutical company and Jiangsu Aidea Pharmaceutical Co., Ltd (Aidea Pharma) an innovative pharmaceutical company in China on Monday, November 13, 2023, officially signed a strategic cooperation agreement in Yangzhou, China. The agreement aims to promote and address medical challenges through the use of innovative drugs especially in the treatment of over 1.9 million HIV-infected people in Nigeria.

The two companies agreed to share and combine their respective resources, technical expertise and positions in the market to collaborate on project development, market expansion, and other aspects by integrating their competitive advantages in the pharmaceutical field. Both companies will engage in multi-level and multi-form cooperation, including but not limited to product manufacturing, promotions and sales, and clinical research, involving existing products and pipeline projects.

At the signing ceremony, Dr. Heliang Fu, Chairman of Aidea Pharma, stated, "This collaboration marks an important step for Aidea Pharma in its commitment to global medical cooperation. By integrating our expertise and experience in the field of innovative drugs, we are confident in bringing greater well-being to African patients." Dr. Fidelis A. Ayebae, Managing Director and CEO of Fidson said, "We are eagerly looking forward to this collaboration and we believe that the complementary strengths of both parties will inject new vitality into the medical field in Africa. This is also in line with our commitment "To provide better and more accessible medicines for the people of Africa."

The collaboration holds promise as a significant growth driver for both companies, particularly as a major factor in the development of local pharmaceutical manufacturing in Nigeria. It will also improve the healthcare and medical practice on the continent. It is expected to be a sterling example of in-depth cooperation in the medical field between China and Nigeria.

About Fidson Healthcare Plc

Fidson Healthcare Plc was established in 1995 and listed on the Nigerian Stock Exchange in 2008. The company is mainly engaged in the production and sales of high-quality medicines and healthcare products. At present, Fidson is the largest and most influential pharmaceutical company in Nigeria. The company was the first to manufacture anti-retroviral ARV drugs in sub-Saharan Africa in 2005. Fidson has a large sales network and business scope in the Nigerian market. With over 300 products across several therapeutic classes, Fidson has initiated a strong export drive to expand her footprint on the African continent. www.fidson.com

About Jiangsu Aidea Pharmaceutical Co. Ltd

Jiangsu Aidea Pharmaceutical Co., Ltd was founded in 2009 and listed on the Science and Technology Innovation Board of Shanghai Stock Exchange in 2020. The company focuses on the core development area of anti-HIV drugs and leverages its competitive advantages in the field of human protein. It is oriented towards addressing unmet clinical treatment needs in China and actively explores, develops, and markets innovative drugs.

Aidea Pharma is committed to research and development, building a complete pipeline of anti-retroviral drug (ARV) and has core technical advantages and product first-mover advantages in this field. The company aims to provide patients with a more diverse range of drug choices, continuously meeting the urgent needs for the upgrading of HIV treatment in China and strives to become a leader in the field of HIV treatment. At the same time, the company continues to consolidate its resource advantages in the field of human protein, and actively layout the upstream and downstream industrial ecology in this field.

Enquiries (Fidson Healthcare Plc only):



Yomi Adebajo

Tel: +234 802 314 6760

Company Secretary

Forward-Looking Statements: Investors are cautioned that any forward-looking statements or projections made in this Announcement are subject to risk and uncertainties that may cause actual results to differ materially from those projected.